Stocklytics Platform
Asset logo for symbol GKOS
Glaukos
GKOS51
$119.82arrow_drop_up1.84%$2.17
Asset logo for symbol GKOS
GKOS51

$119.82

arrow_drop_up1.84%

Performance History

Chart placeholder
Key Stats
Open$119.16
Prev. Close$117.65
EPS-2.88
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range117.45
120.15
52 Week Range59.22
126.96
Ratios
EPS-2.88

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

Correlated Companies

Price$804.62
Perf. (24h)
arrow_drop_down2.01%-$16.57
Market Cap$738.87B
Price$569.71
Perf. (24h)
arrow_drop_up1.79%$10.03
Market Cap$527.83B
Price$160.64
Perf. (24h)
arrow_drop_up0.62%$1.00
Market Cap$382.01B
Price$185.16
Perf. (24h)
arrow_drop_up1.64%$2.99
Market Cap$326.96B

About Glaukos (GKOS)

Glaukos Corp (GKOS) is a medical technology and pharmaceutical company that focuses on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. The company's flagship product, iStent, is the smallest medical device ever approved by the U.S. Food and Drug Administration (FDA) and is designed to improve the natural flow of fluid in the eye and lower intraocular pressure. Glaukos also develops other innovative therapies, including the iStent inject and the iStent supra, which further enhance the treatment options for glaucoma patients.
The stock price history of Glaukos Corp over the past several years has shown significant growth and volatility. In 2016, the stock started trading at around $19 per share and reached a peak of over $70 per share in 2018. However, the stock price has since experienced fluctuations and currently trades at around $45 per share. While the stock has faced some challenges, including regulatory uncertainties and competitive pressures, Glaukos Corp's innovative products and strong financial performance have positioned the company for long-term success.
Sector
Healthcare
Industry
Medical Devices
CEO
Mr. Thomas William Burns
Headquarters
Aliso Viejo
Employees
783
Exchange
NYSE
add Glaukos to watchlist

Keep an eye on Glaukos

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is Glaukos's (GKOS) price per share?
The current price per share for Glaukos (GKOS) is $119.82. The stock has seen a price change of $2.17 recently, indicating a 1.84% change. This reflects the stock's recent market performance and investor sentiment.
help
What is the 52-week high and low for Glaukos (GKOS)?
For Glaukos (GKOS), the 52-week high is $126.96, which is 5.96% from the current price. The 52-week low is $59.22, the current price is 102.33% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help
Is Glaukos (GKOS) a growth stock?
Glaukos (GKOS) has shown an average price growth of 0.41% over the past three years. It has received a score of 80 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Glaukos as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help
What is Glaukos (GKOS) stock price performance year to date (YTD)?
As of the latest data, Glaukos (GKOS) has a year-to-date price change of 55.45%. Over the past month, the stock has experienced a price change of 6.5%. Over the last three months, the change has been 19.69%. Over the past six months, the figure is 32.11%. Looking at a longer horizon, the five-year price change stands at 58.83%.
help
Is Glaukos (GKOS) a profitable company?
Glaukos (GKOS) has a net income of -$134.66M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 75.99% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -31.93% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $314.71M, with a revenue growth rate of 11.26%, providing insight into the company's sales performance and growth. The gross profit is $239.14M. Operating income is noted at -$128.7M. Furthermore, the EBITDA is -$86.98M.
help
What is the market capitalization of Glaukos (GKOS)?
Glaukos (GKOS) has a market capitalization of $6.63B. The average daily trading volume is 613.9K, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level